Transcript
ReachMD Announcer:
Welcome to ReachMD. This medical industry feature is titled “New Trial Device Opens Blood-Brain Barrier to Treat Glioblastoma” featuring Dr. Brian Gill, a neurosurgeon at NewYork-Presbyterian and Columbia. This video is a production of NewYork-Presbyterian with world-class doctors from Columbia & Weill Cornell Medicine.
Dr. Gill:
One of the biggest challenges we have in treating glioblastoma is the blood-brain barrier. Here at NewYork-Presbyterian, we are one of the centers for the SONOBIRD clinical trial, which is testing implantation of this device after surgical resection of glioblastoma, of recurrent glioblastoma, specifically, in combination with intravenous delivery of the microbubbles and carboplatin, and to see if that’s more efficacious than standard of care.
The SonoCloud-9 device is an implantable focused ultrasound device, which combines focused ultrasound waves with intravenous delivery of microbubbles to locally open up the blood-brain barrier in the region of the tumor.
We were able to do this because we placed the SonoCloud-9 implant right in the region of the craniotomy. As a result, those focused ultrasound waves are directed straight into the tumor bed.
This trial is open and enrolling, and we're really excited to offer it to patients with recurrent glioblastoma. We believe that it builds on the exciting results of the phase one and phase two clinical trials using this device, which showed that it's safe, but also showed some promising data with regards to efficacy. And now this study is going to be able to validate that.
ReachMD Announcer:
If you missed any part of this discussion or to find other programs in this series, visit ReachMD.com/industryfeature. This is ReachMD. Be part of the knowledge.
